- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06057870
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
This is a feasibility pilot study that will recruit 20 patients. The investigators plan to determine the feasibility of wearable devices to remotely monitor daily activity (e.g., physical activity, sedentary time, sleep), cognitive function, blood pressure, and weight in patients with decompensated cirrhosis, by assessing patient compliance. A patient is considered compliant if they wear the wristwatch at least 10 hours per day and use the Apps, body weight scale, and blood pressure monitor for at least 4 of 7 days
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with an admission diagnosis of decompensated cirrhosis based on Child-Turcotte-Pugh score of ≥ 7 or MELD-Na score ≥ 15, measured prior to discharge from the hospital. Cirrhosis of any etiology may be included. However, patients with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for three months or more before study inclusion.
2.4.2 18 years or older 2.4.3 Ambulatory (use of walking aids, such as cane and rollator, is acceptable) 2.4.4 Have an understanding, ability, and willingness to fully comply with study procedures and restrictions as determined by the principal investigator.
2.4.5 Informed consent obtained from the subject and the ability of the subject to comply with the requirements of the study.
Exclusion Criteria:
- 2.5.1 Using a pacemaker, implantable cardiac defibrillator, neurostimulator, implantable hearing aids, cochlear implants, or other electronic medical equipment. However, removable hearing aids are permitted.
2.5.2 Presence of advanced or terminal stage hepatocellular carcinoma 2.5.3 Patients with current extrahepatic malignancies including solid tumors and hematologic disorders 2.5.4 Patients with an ongoing ACLF (see diagnostic criteria in reference16) 2.5.5 Patients with a history of significant extrahepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD >2, chronic kidney disease defined by KDIGO criteria, or under renal replacement therapy.
2.5.6 Presence of any extra-hepatic malignancy not in remission for > 12 months 2.5.7 Pregnancy, since being pregnant may alter heart rate and sleep patterns. Women of childbearing age remain eligible.
2.5.8 Inability or refusal to provide informed consent by the patient 2.5.9 Patients with hepatic encephalopathy New Haven grade 1 or greater. 2.5.10 Any records flagged "break the glass" or "research opt out."
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and acceptability of using remote health monitoring
Time Frame: up to 1 year
|
To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
After the 3-month study period, the participants can opt to remain in contact using the App.
If they agree, they will be contacted at 6 months and a year.
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002606
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis, Alcoholic
-
Pharmicell Co., Ltd.RecruitingAlcoholic CirrhosisKorea, Republic of
-
University Hospital, MontpellierNarbonne Hospital; University Hospital, NîmesTerminatedAlcoholic Liver Disease | Alcoholic CirrhosisFrance
-
Assistance Publique - Hôpitaux de ParisCompletedAlcoholic Hepatitis | Alcoholic CirrhosisFrance
-
Pharmicell Co., Ltd.CompletedAlcoholic Liver CirrhosisKorea, Republic of
-
Stempeutics Research Pvt LtdCompletedAlcoholic Liver CirrhosisIndia
-
Yonsei UniversityUnknownAlcoholic Liver CirrhosisKorea, Republic of
-
Conatus Pharmaceuticals Inc.TerminatedLiver Diseases | Liver Cirrhosis | Liver Fibrosis | NASH Fibrosis | Decompensated Non-Alcoholic Steatohepatitis Cirrhosis | Orthotopic Liver TransplantationUnited States
-
Pharmicell Co., Ltd.UnknownAlcoholic Liver CirrhosisUnited States
-
Pharmicell Co., Ltd.CompletedAlcoholic Liver CirrhosisKorea, Republic of
-
Nantes University HospitalCompleted
Clinical Trials on Application on Apple watch
-
Case Comprehensive Cancer CenterNot yet recruitingGlioblastoma | Seizures | Venous ThromboembolismUnited States
-
Stanford UniversityNot yet recruiting
-
Mayo ClinicEnrolling by invitationAtrial FibrillationUnited States
-
Stanford UniversityMedeloop.aiNot yet recruitingComplex Regional Pain SyndromesUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationAtrial Fibrillation | Wearable Electronic DevicesNetherlands
-
Umm Al-Qura UniversityCompleted
-
Umm Al-Qura UniversityCompleted
-
University Hospital HeidelbergThe German Heart Foundation; Klaus Tschira Stiftung, Germany; Freunde und Förderer...Completed
-
Cardiologs TechnologiesCompleted